# Olema Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/olema-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.olemapharma.com
- Total disclosed funding: $141M
- Latest round: Series C (Sep 30, 2020)
- Investors on record: 15

## About

Olema Pharmaceuticals, Inc. is focused on developing and commercializing innovative treatments for breast cancer, particularly targeting advanced or metastatic cases in patients with specific treatment history.Founded in 2007, Olema Pharmaceuticals, Inc. operates from San Francisco, US, and specializes in oncology. The company underwent a significant funding round on November 18, 2020, raising USD 50.00 mn through a VENTURE DEBT financing led by Silicon Valley Bank, contributing to a total of USD 130.00 mn raised to date. The CEO is Sean Bohen, with Cyrus Harmon as the founder.Olema Pharmaceuticals primarily develops innovative therapies for breast cancer, exemplified by their lead candidate, Palazestrant (OP-1250). This once-daily oral treatment targets advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in patients facing disease progression after prior treatments. Olema aims to meet significant medical needs in oncology, enhancing patient quality of life, especially in high-incidence markets like the United States and Europe.Olema Pharmaceuticals generates revenue through partnerships and collaborations within the oncology sector. Their business model involves direct agreements with healthcare institutions and pharmaceutical distributors, facilitating access to their therapies. This includes upfront payments, milestone payments linked to development milestones, and royalties from Palazestrant sales, adhering to industry standards for specialty pharmaceuticals.Looking ahead, Olema Pharmaceuticals plans to expand its product portfolio with new therapies aimed at breast cancer, leveraging funds from their recent IPO, where they raised USD 209.00 mn by selling 11 million shares at USD 19 per share on Nasdaq in November 2020. The company is also focused on entering new markets, including additional regions in Europe and Asia, by 2024, thus enhancing their global footprint.

## Funding rounds

- Series C, Sep 30, 2020, $87M — OrbiMed Advisors, Venrock, Vivo Capital, Wellington Management, Surveyor Capital, BlackRock, Foresite Capital, Deerfield Management, BVF Partners, RA Capital Management, Cormorant Asset Management, Avoro Capital Advisors, Janus Henderson Investors, Logos Capital
- Series B, Jun 18, 2020, $54M — Foresite Capital, BVF Partners, RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Surveyor Capital, Logos Capital, Venrock Healthcare Capital Partners

## Investors

- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B, Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Janus Henderson Investors — Series B, Series C
- Surveyor Capital — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Avoro Capital Advisors — Series C